J&J Takes The Lead In Settling SEC/DoJ Foreign Corrupt Practices Act Probe
This article was originally published in PharmAsia News
Executive Summary
Johnson & Johnson agreed to pay $70 million to resolve charges by the Securities and Exchange Commission and the Department of Justice that the company bribed doctors in several European countries to order or prescribe its products in violation of the Foreign Corrupt Practices Act
You may also be interested in...
Attorney Richard Cassin On FCPA’s Impact On Foreign Acquisitions And Competitor Snitching: An Interview With PharmAsia News
Pharmaceutical companies face stepped up scrutiny of acquisitions and the possibility that competitors will point fingers at suspected fraud in order to lessen their own enforcement actions and penalties.
Attorney Richard Cassin On FCPA’s Impact On Foreign Acquisitions And Competitor Snitching: An Interview With PharmAsia News
Pharmaceutical companies face stepped up scrutiny of acquisitions and the possibility that competitors will point fingers at suspected fraud in order to lessen their own enforcement actions and penalties.
Translating The Foreign Corrupt Practices Act Into Practice: U.S. DoJ/SEC Offer Pragmatic Enforcement Guide
The FCPA resource guide gives examples of cases the DoJ and SEC have decided not to prosecute and describes the hallmarks of an effective compliance program; PhRMA, GPhA among groups that were asking for more clarity.